Summary of AEFI Reports in Ontario

An AEFI report refers to a report received by the PHU, which pertains to one individual vaccine recipient who reported at least one adverse event after receiving the COVID-19 vaccine (i.e., temporally associated with the vaccine). COVID-19 vaccines may be administered concomitantly with, or at any time before or after non-COVID-19 vaccines including live, non-live, adjuvanted, or unadjuvanted vaccines for people 6 months of age or older.[6] See Table 1 for a summary of all AEFI reports received to date in Ontario.

Table 1. Summary of AEFI reports by COVID-19 vaccine product: Ontario, December 13, 2020 to May 19, 2024

	Pfizer-BioNTech Comirnaty	Pfizer-BioNTech Comirnaty Bivalent BA.4/5	Pfizer-BioNTech Comirnaty XBB.1.5	Moderna Spikevax	Moderna Spikevax Bivalent BA.1	Moderna Spikevax Bivalent BA.4/5	Moderna Spikevax XBB.1.5	AstraZeneca Vaxzevria/ COVISHIELD	Janssen Jcovden (Johnson & Johnson)	Novavax Nuvaxovid	All vaccine products combined
Total number of AEFI reports	13,722	225	100	7,307	198	22	82	1,701	20	37	23,415
Number of non-serious reports	13,017	207	93	6,908	186	21	71	1,568	20	37	22,129
Number of serious reports	705	18	7	399	12	1	11	133	0	0	1,286
Proportion of total AEFI reports that are serious (%)	5.1	8.0	7.0	5.5	6.1	4.5	13.4	7.8	0.0	0.0	5.5
Doses administered	23,619,626	2,317,334	1,720,330	9,634,538	1,256,504	140,947	692,439	1,087,759	4,006	16,677	40,493,562
Total reporting rate per 100,000 doses administered	58.1	9.7	5.8	75.8	15.8	15.6	11.8	156.4	499.3	221.9	57.8
Serious reporting rate per 100,000 doses administered	3.0	0.8	0.4	4.1	1.0	0.7	1.6	12.2	0.0	0.0	3.2

Notes:

- The columns above for Pfizer-BioNTech Comirnaty and Moderna Spikevax COVID-19 vaccines include AEFIs associated with all indicated dosages: 3 mcg, 10 mcg and 30 mcg for Pfizer-BioNTech Comirnaty and 25 mcg, 50 mcg and 100 mcg for Moderna Spikevax. Moderna Spikevax Bivalent BA.1 (50 mcg), Moderna Spikevax Bivalent BA.4/5 (50 mcg) and Pfizer-BioNTech Comirnaty Bivalent BA.4/5 (10 mcg and 30 mcg) COVID-19 vaccines are presented separately and were previously recommended vaccine products before the approval of the XBB.1.5-containing COVID-19 mRNA vaccines. Currently, Pfizer-BioNTech Comirnaty XBB.1.5 and Moderna Spikevax XBB.1.5 COVID-19 vaccines are approved and recommended for vaccinating individuals who were not previously vaccinated and as additional doses for those previously vaccinated in approved age groups.
- Novavax Nuvaxovid includes Novavax Nuvaxovid and Novavax Nuvaxovid XBB.1.5 Omicron subvariant COVID-19 vaccines.
- One AEFI report did not specify a vaccine product received.
- Reporting rate for the Janssen Jcovden (Johnson & Johnson) and Novavax Nuvaxovid COVID-19 vaccines should be interpreted with caution due to unstable reporting rate arising from the relatively small number of doses administered.

Data Source: CCM, COVaxON (see technical notes for details on data sources)